Signatera Clinical Oncology Specialist
CurrentResponsible for promoting Signatera, a first of it's kind personalized tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer.